Earnings · China A-shares
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A (300255) earnings
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. Class A published its Q3 report on 2026-10-29: net profit +15.45% year on year, +10.66% excluding one-off items. Wave Radar's earnings-quality score is 59 of 100 (Questionable). The stock moved +0.68% in the 3 trading days after the report.
- Report
- Q3 report
- Published
- 2026-10-29
- Period end
- 2026-09-30
- Net profit YoY
- +15.45%
- Excl. one-offs YoY
- +10.66%
- Result
- Bad / loss
- Quality score
- 59
- Quality
- Questionable
Stock move after the report
Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.
| After | Return | vs index |
|---|---|---|
| 1 day | +0.10% | — |
| 3 days | +0.68% | — |
| 7 days | +2.73% | — |
| 14 days | -9.65% | — |
Report history
Over the last 8 reports, net profit grew year on year in 6 of them. The stock rose in the 3 trading days after 6 of 6 reports (average +10.18%).
| Report | Published | Net profit | Profit YoY | Excl. one-offs YoY | Revenue YoY | EPS | ROE | 3 days after | 30 days after | 30d vs index |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 Q3 report | 2026-10-30 | -¥37.89M | +15.45% | +10.66% | +8.10% | -0.04 | -3.20% | +0.68% | — | — |
| 2026 interim report | 2026-08-26 | -¥16.76M | +42.38% | +27.75% | -3.21% | -0.02 | -1.40% | +1.29% | -13.33% | -6.33% |
| 2026 Q1 report | 2026-04-29 | ¥5.87M | +55.21% | -57.75% | -1.00% | 0.01 | 0.49% | +17.42% | -9.86% | -10.81% |
| 2025 annual report | 2026-04-29 | -¥357.90M | -43.46% | -24.66% | -15.10% | -0.39 | -25.87% | +17.42% | -9.86% | -10.81% |
| 2025 Q3 report | 2025-10-30 | -¥44.82M | -714.77% | -69.41% | -13.11% | -0.05 | -2.91% | +19.28% | +14.47% | +19.22% |
| 2025 interim report | 2025-08-23 | -¥29.09M | +37.98% | +43.62% | -13.42% | -0.03 | -1.88% | +7.82% | +2.69% | -2.18% |
| 2025 Q1 report | 2025-04-29 | ¥3.78M | +106.13% | +104.86% | -12.10% | 0.00 | 0.24% | +14.56% | +147.08% | +144.50% |
| 2024 annual report | 2025-04-29 | -¥249.48M | +79.88% | +77.24% | -26.92% | -0.27 | -14.79% | +14.56% | +147.08% | +144.50% |
The last 8 reports. Net profit is attributable to shareholders and year-to-date (a Q3 report covers the first nine months). Moves count trading days from the first tradeable session after publication; "30d vs index" is the excess return over CSI 300.
How to read this
Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.